Target the Gene, Silence the Disease
RNAi technology makes it possible to target the genes that cause disease.
Treating diseases with substantial unmet needs demands a unique approach at a fast pace—that’s exactly where we thrive. The platform for our targeted RNAi molecule (TRiMTM) leverages a natural pathway to “silence” genes causing disease. With drug candidates in a growing number of disease areas, TRiMTM has shown it can target genes wherever they are.
What We Do Best
Acceleration
Every day we can save in our development timeline is one day earlier a person may benefit from our future therapies.
Collaboration
We go farther when we work together to reimagine how therapeutics are developed and delivered.
Growth
We don’t let uncertainty keep us from tackling big questions and finding meaningful solutions.
Watch How the TRiMTM Platform Works
Arrowhead has developed a therapeutic RNAi technology called TRiMTM—Targeted RNAi Molecule.
Contact Us
Corporate Headquarters
177 East Colorado Boulevard, Suite 700Pasadena, CA 91105
(866) 80ARROW Directions
Arrowhead Pharmaceuticals Ireland Limited
Registered in Dublin, Ireland (775949)3rd FloorOrmond Building31-36 Ormond Quay UpperDublin 7, D07 EE37, Ireland
Directions
Arrowhead Pharmaceuticals Switzerland GmbH
Dammstrasse 196300 ZugSwitzerland
(866) 80ARROW DirectionsMedia
Paul Graves
Arrowhead Pharmaceuticals, Inc.
Call: +1 (626) 788-8110
media@arrowheadpharma.com
Investors
Vince Anzalone, CFA
Arrowhead Pharmaceuticals, Inc.
Call: +1 (626) 788-8035
ir@arrowheadpharma.com
Safety Reporting
To report an adverse event, please complete this form or send an email to:
safety@arrowheadpharma.com
To report a product complaint, please send an email to:
productcomplaints@arrowheadpharma.com